Oncodesign Services’ Post

Avidity Biosciences (RNA) leads in RNA therapeutics with Del-desiran (AOC 1001), targeting myotonic dystrophy type 1. Pivotal trial soon; approval could significantly boost earnings. Partnership with Bristol Myers Squibb, worth up to $2.3 billion, expands collaboration. Major clinical update for AOC 1001 expected by mid-2025; success could validate Avidity’s platform. Bullish on RNA above $24.00-$24.50, targeting $34.00-$35.00. Avidity's innovative approach presents significant growth potential. #AvidityBiosciences #RNA #Biotech #MyotonicDystrophy #ClinicalTrials #Innovation #Investing

Are you curious about AVITHRAPID's WP3 (Istituto Nazionale Malattie Infettive "Lazzaro Spallanzani" IRCCS – Italy)? Take a look below! 🔎 👇  📑 Work Packages #Drugdiscovery is a multidisciplinary effort. AVITHRAPID brings together a team of highly skilled experts in molecular modeling, structural biology, assay development, toxicity profiling, antiviral drug discovery, animal model testing, and clinical trials.  Several partners have successfully worked on the discovery of novel antiviral substances. In addition, one pharma partner has identified a small molecule drug against #Zika #virus that is ready to enter #clinical #trials. The unique portfolio of substances ranges from validated hits to pre-clinical candidates with proven in vivo efficacy. To further develop and validate this portfolion the AVITHRAPID consortium will work together in 8 Work Packages (WPs) which operate as an integrated pre-clinical drug discovery value chain.

CNS disorders present unique clinical research challenges, but smaller #biotech firms are stepping up. 💸 In April, Contineum Therapeutics raised $110M through an IPO to study the biological pathways associated with disabling neurological and inflammatory diseases. With major players avoiding this challenging TA, other emerging companies have a huge opportunity to attract investor interest and advance their groundbreaking treatments. Learn about the top therapeutic areas getting attention from investors and other funding trends in our latest report: https://bit.ly/3SX8iKx

I’m delighted to announce the start of Kariya Pharmaceuticals' Phase 1 trial and successful dosing of the first cohort with KP405, a novel, brain-penetrant, dual incretin (GLP-1/GIP) receptor agonist for the treatment of Parkinson’s Disease. I am beyond proud of our team Mikael Thomsen, Christian Hölscher, René Egebro, and Kaare Gyberg Rasmussen, and wish to also thank Mark Dale, John Connell, Grace Hawes, and the rest of the MAC Clinical Research team, as well as our partners (Syngene International Limited, ERBC GROUP, Bachem, Bioneer A/S, Porton Pharma Solutions Ltd., Alderley Analytical Ltd), and our financiers (BioInnovation Institute, BNC KOREA, Inc., and Innovation Fund Denmark), who each played a critical part in getting us here. KP405 is poised to be first to market in this promising new drug class, and we celebrate this milestone as we bring this life-changing drug one step closer to patients in need. https://lnkd.in/dsMxnuh9 #PhaseI #firstinhuman #clinicaldevelopment #endparkinsonsdisease #cureparkinsonsdisease #parkinsonsresearch #parkinsonsdisease #movementdisorders #patientsarewaiting #hope #BioInnovationInstitute #DKlifescience #DKBiotek #neuroscience #CNS #onestepcloser

ENEA-Tech Biomedical Foundation Invests €6m in BetaGlue Therapeutics – Brings 2024 Funding Round Total to €24m https://lnkd.in/dskZRtQn BetaGlue Therapeutics ENEA Tech e Biomedical Salvatore Calabrese Colin Story Maria Cristina Porta More European life science business news at [LSE] Life-Sciences-Europe.com __

EIP is a Key meeting to stay up on current immunogenicity analysis techniques and guidance.

Here we go! The 23rd Precision in Drug Discovery & Preclinical Summit (#PDDP) is ready to launch! Stop by BOOTH #4 to talk all things preclinical research, preclinical models, and the power of advanced #histology services to accelerate and advance your drug discovery goals. #preclinicalresearch #preclinicalmodels #histology #digitalpathology #ihc

Are you curious about AVITHRAPID's WP1 (Università degli Studi di Napoli Federico II (UniNa) / University of Naples Federico II)? Take a look below! 🔎 👇 📑 Work Packages #Drugdiscovery is a multidisciplinary effort. AVITHRAPID brings together a team of highly skilled experts in molecular modeling, structural biology, assay development, toxicity profiling, antiviral drug discovery, animal model testing, and clinical trials. Several partners have successfully worked on the discovery of novel antiviral substances. In addition, one pharma partner has identified a small molecule drug against #Zika #virus that is ready to enter #clinical #trials. The unique portfolio of substances ranges from validated hits to pre-clinical candidates with proven in vivo efficacy. To further develop and validate this portfolion the AVITHRAPID consortium will work together in 8 Work Packages (WPs) which operate as an integrated pre-clinical drug discovery value chain.

This year’s Life Science nominees at the #NEVYs24 are breaking boundaries and changing lives. From early-stage pioneers to industry powerhouses, these companies are paving the way for the future of the life science industry. Here’s a closer look at the awards up for grabs as these contestants prepare to battle it out next week at #NEVYsSurvivor! 🏆 Emerging Life Science Company of the Year 💡 – Visionary early-stage companies with groundbreaking technologies and ambitious teams who are rewriting the rules: Precede Biosciences  ARTBIO  Diagonal Therapeutics  Clasp Therapeutics  Nvelop Therapeutics Powerhouse Life Science Company of the Year 💪 – Resilient companies that have made waves with IPOs, M&As, or transformative deals, amplifying their impact across the ecosystem: Cerevel Therapeutics  Mariana Oncology  Morphic Therapeutic Neumora Learn more about the rest of the nominees here! https://lnkd.in/e7f7mfDZ #NEVCA #Innovation